GlassScriptPhysician profile
Anees Siddiqui
NPI 1447462940
$5,551.59
in general payments reported to CMS, 2019-2025
19 companies · $4,102 in 2025
The $4,102 reported for 2025 was more than what 89% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.80 · 2021: $101 · 2022: $237 · 2023: $515 · 2024: $578 · 2025: $4,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,578 · Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,578.44 |
| Food and Beverage | $1,616.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,578.44 | 2025 | Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $367.49 | 2021-2025 | Gattex, Eohilia |
| Genzyme Corporation | $251.29 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $215.00 | 2022-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $191.91 | 2023-2025 | Bylvay, Iqirvo |
| Abbvie INC. | $171.73 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $136.37 | 2022-2023 | |
| Qol Medical, LLC | $108.95 | 2023-2025 | Sucraid |
| Daiichi Sankyo INC. | $102.47 | 2024-2025 | Injectafer |
| Mirum Pharmaceuticals, INC. | $81.92 | 2023-2025 | Livmarli, Cholbam |
| Alcresta Therapeutics, INC. | $81.24 | 2023-2025 | Relizorb |
| Pharming Healthcare, INC. | $75.74 | 2023-2024 | Ruconest |
| Mauna Kea Technologies, INC. | $52.14 | 2025 | |
| Albireo Pharma, INC. | $36.73 | 2022 | |
| Travere Therapeutics, INC. | $31.55 | 2023 | Cholbam |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $24.73 | 2024 | |
| Medtronic, INC. | $15.96 | 2022 | |
| Genentech USA, INC. | $15.16 | 2024 | Actemra |
| Amgen INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anees Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.